Double attack on prostate cancer: new combo trial seeks to halt spread
NCT ID NCT05613894
Summary
This early-stage trial is testing the safety and initial effectiveness of combining two treatments for advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The combination pairs a targeted drug (cabozantinib) with a radioactive therapy (177Lu-PSMA-617) that seeks out and delivers radiation directly to cancer cells. The main goal is to find the safest and most effective dose of the drug to use alongside the radiation treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huntsman Cancer Institute at University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.